Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
<h4>Objectives</h4>This meta-analysis was undertaken to systematically evaluate the effects of poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy on the survival of newly diagnosed advanced epithelial ovarian cancer (EOC) patients.<h4>Methods/materials</h4>A s...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0294647 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560394041131008 |
|---|---|
| author | Banghyun Lee Suk-Joon Chang Byung Su Kwon Joo-Hyuk Son Myong Cheol Lim Yun Hwan Kim Shin-Wha Lee Chel Hun Choi Kyung Jin Eoh Jung-Yun Lee Dong Hoon Suh Yong Beom Kim |
| author_facet | Banghyun Lee Suk-Joon Chang Byung Su Kwon Joo-Hyuk Son Myong Cheol Lim Yun Hwan Kim Shin-Wha Lee Chel Hun Choi Kyung Jin Eoh Jung-Yun Lee Dong Hoon Suh Yong Beom Kim |
| author_sort | Banghyun Lee |
| collection | DOAJ |
| description | <h4>Objectives</h4>This meta-analysis was undertaken to systematically evaluate the effects of poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy on the survival of newly diagnosed advanced epithelial ovarian cancer (EOC) patients.<h4>Methods/materials</h4>A systematic literature search revealed 3,227 studies. A subsequent selection process identified seven suitable randomized studies that assessed the survival outcomes in newly diagnosed advanced EOC patients administered PARPi (n = 1921; the PARPi group) or placebo (n = 1150; the placebo group). The survival outcomes were compared with respect to the PARPi treatment regardless of bevacizumab maintenance therapy. All adverse events ≥ grade 3 were analyzed. Review Manager Version 5.4.1 software was used for the meta-analysis.<h4>Results</h4>The two-year progression-free survival (PFS) was significantly better in the PARPi group than the placebo (Hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.41 to 0.68). Furthermore, patients in the PARPi group with the BRCA1/2 mutation (BRCAm), BRCA wild type, homologous-recombination deficiency (HRD), or HRD without BRCAm, but not with homologous-recombination proficiency had a significantly better two-year PFS than the patients in the placebo group. The five-year overall survival (OS) was comparable in the two groups, but patients in the PARPi group with BRCAm had a significantly better five-year OS than those in the placebo group (HR, 0.57; 95% CI, 0.44 to 0.74). In addition, the adverse event rate (≥ grade 3) was significantly higher in the PARPi group than in the placebo group (HR, 2.94; 95% CI, 1.13 to 7.63).<h4>Conclusions</h4>In patients with newly diagnosed advanced EOC, PARPi maintenance therapy was significantly more effective in terms of survival than no PARPi treatment. However, the risk of serious adverse events was higher for patients who received PARPi maintenance therapy. |
| format | Article |
| id | doaj-art-29fb728cd4b84bb393db5259b4f25880 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-29fb728cd4b84bb393db5259b4f258802025-01-04T05:31:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-011811e029464710.1371/journal.pone.0294647Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.Banghyun LeeSuk-Joon ChangByung Su KwonJoo-Hyuk SonMyong Cheol LimYun Hwan KimShin-Wha LeeChel Hun ChoiKyung Jin EohJung-Yun LeeDong Hoon SuhYong Beom Kim<h4>Objectives</h4>This meta-analysis was undertaken to systematically evaluate the effects of poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy on the survival of newly diagnosed advanced epithelial ovarian cancer (EOC) patients.<h4>Methods/materials</h4>A systematic literature search revealed 3,227 studies. A subsequent selection process identified seven suitable randomized studies that assessed the survival outcomes in newly diagnosed advanced EOC patients administered PARPi (n = 1921; the PARPi group) or placebo (n = 1150; the placebo group). The survival outcomes were compared with respect to the PARPi treatment regardless of bevacizumab maintenance therapy. All adverse events ≥ grade 3 were analyzed. Review Manager Version 5.4.1 software was used for the meta-analysis.<h4>Results</h4>The two-year progression-free survival (PFS) was significantly better in the PARPi group than the placebo (Hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.41 to 0.68). Furthermore, patients in the PARPi group with the BRCA1/2 mutation (BRCAm), BRCA wild type, homologous-recombination deficiency (HRD), or HRD without BRCAm, but not with homologous-recombination proficiency had a significantly better two-year PFS than the patients in the placebo group. The five-year overall survival (OS) was comparable in the two groups, but patients in the PARPi group with BRCAm had a significantly better five-year OS than those in the placebo group (HR, 0.57; 95% CI, 0.44 to 0.74). In addition, the adverse event rate (≥ grade 3) was significantly higher in the PARPi group than in the placebo group (HR, 2.94; 95% CI, 1.13 to 7.63).<h4>Conclusions</h4>In patients with newly diagnosed advanced EOC, PARPi maintenance therapy was significantly more effective in terms of survival than no PARPi treatment. However, the risk of serious adverse events was higher for patients who received PARPi maintenance therapy.https://doi.org/10.1371/journal.pone.0294647 |
| spellingShingle | Banghyun Lee Suk-Joon Chang Byung Su Kwon Joo-Hyuk Son Myong Cheol Lim Yun Hwan Kim Shin-Wha Lee Chel Hun Choi Kyung Jin Eoh Jung-Yun Lee Dong Hoon Suh Yong Beom Kim Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. PLoS ONE |
| title | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. |
| title_full | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. |
| title_fullStr | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. |
| title_full_unstemmed | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. |
| title_short | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. |
| title_sort | impact of parp inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer a meta analysis |
| url | https://doi.org/10.1371/journal.pone.0294647 |
| work_keys_str_mv | AT banghyunlee impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT sukjoonchang impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT byungsukwon impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT joohyukson impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT myongcheollim impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT yunhwankim impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT shinwhalee impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT chelhunchoi impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT kyungjineoh impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT jungyunlee impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT donghoonsuh impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis AT yongbeomkim impactofparpinhibitormaintenancetherapyinnewlydiagnosedadvancedepithelialovariancancerametaanalysis |